Standard BioTools (Standard BioTools) COGS-to-Revenue

: 0.53 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

Standard BioTools's Cost of Goods Sold for the three months ended in Dec. 2023 was $14.8 Mil. Its Revenue for the three months ended in Dec. 2023 was $28.2 Mil.

Standard BioTools's COGS to Revenue for the three months ended in Dec. 2023 was 0.53.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Standard BioTools's Gross Margin % for the three months ended in Dec. 2023 was 47.39%.

Standard BioTools COGS-to-Revenue Historical Data

The historical data trend for Standard BioTools's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Standard BioTools Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

0.45

0.40

0.47

0.62

0.53

Standard BioTools Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue																0.59	0.52	0.51	0.56	0.53

Standard BioTools COGS-to-Revenue Calculation

Standard BioTools's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	55.89	/	106.34
	=	0.53

Standard BioTools's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	14.831	/	28.188
	=	0.53

Standard BioTools (NAS:LAB) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Standard BioTools's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	14.831 / 28.188
	=	47.39 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Standard BioTools COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Standard BioTools's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Standard BioTools (Standard BioTools) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Standard BioTools Inc (NAS:LAB) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

FLB:Germany FLB:Germany

Address

2 Tower Place, Suite 2000, South San Francisco, CA, USA, 94080

Website

https://www.standardbio.com

Standard BioTools Inc manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. The company's segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Executives

Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
Jeffrey G. Black	officer: SVP & Chief Financial Officer	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Casdin Partners Fo1-msv, Lp	director	C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii Gp, Llc	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii, L.p.	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Fenel M Eloi	director	C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Caligan Partners Lp	10 percent owner	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Frank Witney	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Jeremy Steven Davis	officer: SVP Chief Commercial Officer	C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Hanjoon Alex Kim	officer: Chief Operating Officer	C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Michael Egholm	director, officer: President & CEO	1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110